WELL Health has a “massive” opportunity, this analyst says

Beacon Securities analyst Gabriel Leung maintained his “Buy” rating on Well Health Technologies (Well Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) with an unchanged 12-month price target of C$9.00.

In his May 7 corporate update, Leung remained bullish on Well Health’s positioning as a consolidator in Canada’s healthcare market. He noted the company’s ability to execute a high-ROIC strategy while divesting from volatile U.S. assets.

“Despite being the largest provider network in Canada, WELL continues to hold only low single-digit market share, suggesting a massive consolidation opportunity,” Leung said. “We continue to believe that WELL remains one of the best-positioned acquirers given its shared service and technology infrastructure, which should help to drive meaningful efficiencies within acquired clinics.”

He said Wellstar’s AI-powered Nexus platform and its integration with Healwell’s tech stack could drive new revenue, particularly with national programs supporting AI scribes.

Wellstar and Healwell are affiliated initiatives operating under the umbrella of Well Health Technologies.

“We’d also note that Wellstar/Healwell (Buy, TP: $3.50) cross-selling activity appears in good shape as evidenced by Wellstar’s launch of its Nexus AI platform, which will serve as the hub for expanding automated AI and agentic capabilities (powered by Healwell technology),” Leung said. “The platform’s first feature will be an AI medical scribe enabling real-time clinical documentation across care settings (powered, we believe, by Healwell’s Mutuo Health Solutions AutoScribe platform).”

Leung thinks Well Health will generate $195-million in adjusted EBITDA on $1,403-million in revenue for fiscal 2025. He expects those numbers to decline to $177-million in adjusted EBITDA on $1,514-million in revenue in 2026.

Beacon revised its 2026 EBITDA estimate downward primarily due to lower expected contribution from WELL’s Circle Medical business, which faces profitability challenges and a reduced revenue forecasted.

Beacon attended a presentation by Well Health on May 6 and heard from Healwell’s incoming (starting July 1st) CEO, James Lee, at an open panel.

“While specific details are yet to be revealed (given that Mr. Lee has not stepped into the role officially yet), we believe that Mr. Lee’s priority will be on driving consolidated operating margins to the double-digit range (from, by our estimates, largely breakeven currently), along with integration efforts, which include cross-selling Healwell’s AI tools into Orion Health’s large healthcare system customer base,” Leung said. “We understand that there are currently two proof-of-concepts running, highlighting early cross-selling success.”

Leung said Beacon understands that Well Health, Wellstar and Healwell are pursuing a $500-million Canadian healthcare technology pipeline, a market the trio is well-positioned to tap into given Well Health’s strong platform and growing “Buy Canada” sentiment.

“Overall, we were pleased with the update and believe WELL remains well-positioned to capitalize on the large opportunity before it,” he said.

Disclosure: Nick Waddell owns shares of WELL and the company is an annual sponsor of Cantech Letter.

-30-